已收盤 10-24 16:00:00 美东时间
-0.220
-0.21%
今日重点评级关注:Ascendiant Capital:维持PAVmed"买入"评级,目标价从19美元升至20美元;Ascendiant Capital:维持Plus Therapeutics"买入"评级,目标价从20.5美元升至21美元
10-07 15:04
Barclays analyst William Grippin maintains Veralto (NYSE:VLTO) with a Overweight and lowers the price target from $120 to $119.
10-06 23:46
今日重点评级关注:Maxim Group:维持T Stamp"买入"评级,目标价从8美元升至12美元;Maxim Group:维持Rezolute"买入"评级,目标价从15美元升至20美元
09-22 18:44
During the last three months, 5 analysts shared their evaluations of Veralto (N...
09-19 22:00
Barclays analyst William Grippin initiates coverage on Veralto (NYSE:VLTO) with a Overweight rating and announces Price Target of $120.
09-19 19:58
WALTHAM, Mass., Sept. 18, 2025 /PRNewswire/ -- Veralto (NYSE: VLTO), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital Resourc...
09-18 20:00
Providing a diverse range of perspectives from bullish to bearish, 4 analysts h...
08-27 05:01
Raymond James analyst Bobby Zolper initiates coverage on Veralto (NYSE:VLTO) with a Market Perform rating.
08-26 21:56
Stifel analyst Nathan Jones maintains Veralto (NYSE:VLTO) with a Buy and raises the price target from $116 to $120.
07-30 20:31
Veralto (NYSE:VLTO) raises FY2025 Adj EPS guidance from $3.60-$3.70 to $3.72-$3.80 vs $3.69 analyst estimate..
07-29 04:31